Healthcare Services

Global Oncolytic Virus Therapy Market 2026–2030: Forecast Insights for Business Planning

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oncolytic virus therapy market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Oncolytic Virus Therapy Market?

The oncolytic virus therapy market has experienced substantial expansion in recent years. This market is projected to grow from $0.23 billion in 2025 to $0.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. The historical increase can be attributed to factors such as the development of hsv- and adenovirus-based oncolytic therapies, the execution of early clinical trials for melanoma and breast cancer, a rising interest from cancer research institutes, increasing government funding for virotherapy research, and a growth in collaborations between biotech companies and academic institutions.

The oncolytic virus therapy market is projected to experience substantial expansion over the coming years, reaching a valuation of $0.68 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.7%. This anticipated growth during the forecast period is driven by several factors, including an escalating demand for genetically engineered oncolytic viruses, their increasing application in treating lung, prostate, and brain cancers, the proliferation of specialized clinics and hospitals providing virotherapy, growing investment in combination and novel virus therapies, and the expansion of clinical trial infrastructure within developing markets. Key trends expected during this period encompass the growing integration of AI and big data in oncolytic virus research, enhanced utilization of genomics and precision medicine for designing therapies, broader deployment of digital platforms for overseeing clinical trials, increased automation in virus manufacturing and quality control, and the expansion of IoT-based systems for monitoring virus storage and distribution.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Drivers Are Supporting The Rise Of The Oncolytic Virus Therapy Market?

The growing occurrence of cancer cases is anticipated to drive the expansion of the oncolytic virus therapy market in the future. Cancer refers to a collection of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells within the body. Oncolytic virus therapy has the capability to selectively attack and eliminate cancer cells, simultaneously boosting an immune reaction against the tumor, thus offering a two-pronged approach for successful cancer treatment. For example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, reported a projection of over 35 million new cancer cases by 2050. This signifies a 77% rise from the estimated 20 million cases recorded in 2022. Consequently, the rising incidence of cancer cases is fueling the growth of the oncolytic virus therapy market.

What Segments Are Identified Within The Structure Of The Oncolytic Virus Therapy Market?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Trends Are Expected To Impact The Competitive Landscape Of The Oncolytic Virus Therapy Market?

Key companies operating within the oncolytic virus therapy market are primarily focused on acquiring regulatory approvals to hasten the launch of new cancer treatment solutions. Regulatory approvals denote the formal procedure through which health authorities assess and sanction medical products, encompassing drugs, biologics, and medical devices, for commercial availability. For instance, in March 2024, ImmVira, a China-based biotechnology firm, was granted Fast Track designation by the FDA for MVR-T3011 IT, its oncolytic virus therapy. This therapy targets recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have shown disease progression subsequent to platinum-based chemotherapy and at least one previous line of anti-PD-1/PD-L1 therapy. Such a designation is designed to accelerate the development and review of therapies intended for serious conditions with existing unmet medical needs.

Which Key Players Are Driving Competition In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Region Currently Holds The Largest Share Of The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncolytic Virus Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Infectious Disease Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795